Medical/Pharmaceuticals

Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors

Presentation to feature first-in-human results for ISM6331, a novel, AI-designed pan-TEAD inhibitor targeting the Hippo pathway Global Phase 1 multicenter study evaluates safety, tolerability, and preliminary efficacy in patients with mesothelioma and other advanced solid tumors CAMBRIDGE, Mass...

2026-07-27 20:00 9203

Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565

CHENGDU, China, July 27, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) today announced that it has received a clinical trial notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA)...

2026-07-27 19:40 6611

Articura Launches a New Chapter for Sovereign Healthcare AI in Indonesia

Hospitals, clinics, academia and industry join a collaborative ecosystem designed to advance trusted, nationally grounded healthcare AI JAKARTA, Indonesia, July 27, 2026 /PRNewswire/ -- PT Articura Tech Indonesia ("Articura")today announced the foundation of its Sovereign Healthcare AI Platform,...

2026-07-27 19:02 16438

Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model

-ASC37 demonstrated statistically significant 88% greater relative body weight reduction compared to tirzepatide in the diet-induced obese (DIO) mouse model. -Both ASC37 once-monthly subcutaneous (SQ) formulation and oral formulation will be submitted to the U.S. Food and Drug Administration (FDA...

2026-07-27 18:42 7006

Bambusa Therapeutics Reports Potentially Transformative Preliminary Proof-of-Concept Results for BBT001 in Atopic Dermatitis, Reinforcing Its Best-in-Disease Potential

BBT001 delivered highly statistically significant and clinically meaningful improvement in EASI beginning at Week 1, with responses continuing to improve over time Fast-onset and potent itch relief was observed as early as Day 1 after the first dose alongside robust and durable suppression of Ty...

2026-07-27 18:00 6091

Harbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 27, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that it has ent...

2026-07-27 17:02 6255

3Shape's TRIOS MOVE Pro Scanner Cart Wins Red Dot 2026 Design Award

COPENHAGEN, Denmark, July 27, 2026 /PRNewswire/ -- 3Shape, a global innovator in digital dentistry with market-leading intraoral (IOS) scanners, has received this year's 2026 Red Dot Award for its TRIOS MOVE Pro Scanner Cart. The Red Dot Jury posted the following statement: 'The system architectu...

2026-07-27 16:21 3350

Jiangxi Bio's Veterinary Tetanus Antitoxin Production Line Officially Commenced Production,Accelerating Commercialization of the Animal Antiserum Portfolio

HONG KONG, July 27, 2026 /PRNewswire/ -- Jiangxi Institute of Biological Products Inc. and its subsidiaries (collectively, "Jiangxi Bio" or the "Group") (stock code: 6915.HK) is pleased to announce that the veterinary tetanus antitoxin ("Veterinary TAT") production line of Chifeng Bo-en Pharmaceu...

2026-07-27 15:36 8247

Home Control's Orbiva Signs Strategic MOU with Indonesia's Articura to Advance Localized Healthcare AI and AIoT Digital Health Ecosystem

HONG KONG, July 27, 2026 /PRNewswire/ -- Home Control International Limited  ("Home Control" or the "Company", together with its subsidiaries, the "Group"; Stock Code: 1747) is pleased to announce that its wholly-owned subsidiary, Orbiva Limited ("Orbiva"), has entered into a strategic cooperation...

2026-07-27 15:22 8920

IHH Healthcare Expands 'IHH Catalyst' to North Asia to Accelerate Clinical Adoption of Healthcare Innovation

Building on the success of its inaugural programme in India, IHH Healthcare is launching IHH Catalyst | North Asia Edition to help startups in Hong Kong, Chinese Mainland and neighbouring markets turn healthcare innovation into real-world clinical impact. HONG KONG and SINGAPORE and KUALA L...

2026-07-27 11:00 2269

Seaweed extract shown to relieve prostate symptoms

In a breakthrough clinical trial undertaken by Australian biotechnology company Marinova, a unique seaweed extract has been shown to relieve the symptoms of benign prostatic hyperplasia (BPH). HOBART, Australia, July 27, 2026 /PRNewswire/ -- A randomised, double-blind, placebo-controlled clinical...

2026-07-27 07:00 1854

International Self-Care Day: Dimora Medical Highlights Wound Care as an Essential Part of Everyday Self-Care

NEW YORK, July 24, 2026 /PRNewswire/ -- As International Self-Care Day draws attention to the importance of maintaining health around the clock, the concept of 24/7 self-care continues to gain momentum among consumers seeking more proactive approaches to everyday well-being. While nutrition, exer...

2026-07-25 01:50 5001

Nova Biomedical Advances Integrated Cell Line Development Workflows: NanoCellect products are now part of Nova Biomedical

WALTHAM, Mass., July 24, 2026 /PRNewswire/ -- Nova Biomedical today announced a transaction involving certain assets of NanoCellect, a provider of microfluidic cell sorting technology. This expands Nova Biomedical's capabilities in cell line development and strengthens its ability to support bio...

2026-07-24 22:05 5676

Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients

PALMA DE MALLORCA, Spain, July 24, 2026 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, today announced that the last patient has completed their last visit (LPLV) in the company's Phase 2b/3 clinical trial of i...

2026-07-24 09:30 2486

ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406

SHANGHAI, July 24, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial with AK0406, a novel long-acting antiviral-Fc conjugate (AFC) drug for influenza prophylaxis. The clini...

2026-07-24 09:00 3200

Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 23, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a ...

2026-07-24 08:02 7303

Fapon Showcases AI-Engineered Enzymes and Alzheimer's Solutions at ADLM 2026, Reinforcing North American Commitment

ANAHEIM, Calif., July 23, 2026 /PRNewswire/ -- Fapon, a trusted global IVD provider with deepening roots in North America, will exhibit at ADLM 2026 from July 26 to 30 in Anaheim, California. The company will introduce novel AI-engineered enzymes for molecular diagnostics alongside a full suite o...

2026-07-24 01:10 3095

AH-008 Achieves Key Clinical Milestone with Successful First Subject First Dose (FSFD) in Phase I Study for Prevention of Chemotherapy-Induced Peripheral Neuropathy (CIPN)

TAIPEI, July 23, 2026 /PRNewswire/ -- AnHorn Medicines today announced the successful completion of the first subject first dose in the Phase I clinical trial of AH-008, a first-in-class neuroprotective candidate being developed to prevent chemotherapy-induced peripheral neuropathy (CIPN). This m...

2026-07-23 22:00 2739

Zhongchao Inc. Announces $5.0 Million Registered Direct Offering

SHANGHAI, July 23, 2026 /PRNewswire/ -- Zhongchao Inc ("Zhongchao" or the "Company") (NASDAQ: ZCMD), today announced that it has entered into a definitive agreement with certain investors for the purchase and sale of an aggregate of4,545,455 of the Company's Class A Ordinary Shares, par value $0...

2026-07-23 21:00 4546

PUBLIC TRUST IN HEALTH INNOVATION IS SHAPED MORE BY MINDSET THAN DEMOGRAPHICS, DNV RESEARCH FINDS

OSLO, Norway, July 23, 2026 /PRNewswire/ -- Public trust in health innovation may be less predictable than healthcare organizations assume, according to new research from DNV, the independent assurance and certification provider.

2026-07-23 20:34 2109
1 ... 40414243444546 ... 641